Flavio Victor Signorelli
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Hospital Universitário Clementino Fraga/CCS
Unidade:
Hospital Universitário Clementino Fraga/CCS
Departamento:
Divisão Médica DMD/HU
Formação:
-
Hospital das Clínicas da Faculdade de Medicina da USP
| Pós-Doutorado | 2020 - 2022
-
Universidade Federal do Rio de Janeiro
Clinica Médica | Doutorado | 2008 - 2010
-
Universidade Federal do Rio de Janeiro
Clínica Médica | Mestrado | 1999 - 2002
-
Universidade Federal do Rio de Janeiro
| Especialização - Residência medica | 1996 - 1999
-
Universidade Federal Fluminense
medicina | Graduação | 1989 - 1995
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:
(96.30% artigos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An APS ACTION Study | 10.1016/j.labinv.2023.100147 | 2023 |
| Ocular retinal findings in asymptomatic patients with antiphospholipid syndrome secondary to systemic lupus erythematosus | 10.1007/s10067-023-06613-9 | 2023 |
| Comorbid association of obstructive sleep apnea (OSA) and thrombotic primary antiphospholipid syndrome (tPAPS): A more severe phenotype? | 10.1016/j.clim.2023.109781 | 2023 |
| Thrombosis Recurrence and Major Bleeding in Non-anticoagulated Thrombotic Antiphospholipid Syndrome Patients: Prospective Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (-Registry-) | 10.1016/j.semarthrit.2023.152347 | 2023 |
| CoaguChek® XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome | 10.1177/09612033221086134 | 2022 |
| Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome | 10.1177/09612033221102073 | 2022 |
| Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study | 10.1016/j.semarthrit.2022.152113 | 2022 |
| Ocular involvement in primary antiphospholipid syndrome: results of an extensive ophthalmological evaluation performed in the APS-Rio cohort | 10.1177/09612033221143294 | 2022 |
| Ocular findings in asymptomatic patients with primary antiphospholipid syndrome | 10.1177/09612033221133687 | 2022 |
| AB0458-DISEASE ACTIVITY AT CONCEPTION PREDICTS LUPUS FLARE UP TO 2 YEARS AFTER BIRTH: A MULTICENTRE LONG TERM FOLLOW-UP STUDY | 10.1136/annrheumdis-2022-eular.765 | 2022 |
| Distinct features of youth-onset primary antiphospholipid syndrome | 10.1177/09612033211038054 | 2021 |
| Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria | 10.1002/acr.24520 | 2021 |
| Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria? | 10.1177/09612033211033978 | 2021 |
| Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature | 10.1177/0961203320949667 | 2020 |
| Síndrome Antifosfolípide: uma abordagem prática para questões controversas | 2020 | |
| The interplay between tuberculosis and systemic lupus erythematosus | 10.1097/bor.0000000000000493 | 2018 |
| New and Upcoming treatments in Antiphospholipid Syndrome: a comprehensive review | 10.1016/j.phrs.2018.04.012 | 2018 |
| Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update | 10.5152/eurjrheum.2017.17023 | 2017 |
| The role of infections in neuropsychiatric lupus | 10.1177/0961203317691375 | 2017 |
| Antiphospholipid Syndrome On Cloud (APSOnCloud): web-based monitoring of oral anticoagulation | 10.1177/0961203316658558 | 2017 |
| AVALIAÇÃO DA PLAQUETOPENIA RELACIONADA AOS ANTICORPOS ANTIFOSFOLIPÍDIOS | 10.1016/j.rbr.2017.07.485 | 2017 |
| TRIPLA POSITIVIDADE AOS ANTICORPOS ANTIFOSFOLIPÍDIOS: AUMENTO DO RISCO DE MANIFESTAÇÕES GESTACIONAIS | 10.1016/j.rbr.2017.07.527 | 2017 |
| Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases | 10.1007/s10067-015-3030-y | 2016 |
| Patient-health care provider relationship: how can it impact on APS (Hughes' syndrome) adherence to treatment? | 10.1177/0961203314536480 | 2014 |
| 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome | 10.1016/j.autrev.2014.03.002 | 2014 |
| Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients | 10.1007/s00296-007-0447-x | 2008 |
| Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study | 10.1177/0961203308093829 | 2008 |
Eventos:
(44.12% eventos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| COMPARISON OF SINGLE LUPUS ANTICOAGULANT POSITIVITY VERSUS TRIPLE POSITIVITY IN PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS | 10.47660/CBR.2023.2171 | 2023 |
| THE (NON-)RELEVANCE OF ANTI-CELL ANTIBODIES (ANA) IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) | 10.47660/CBR.2023.2124 | 2023 |
| DIFFERENCES BETWEEN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) PATIENTS WITH COMBINED ARTERIAL AND VENOUS EVENTS VERSUS THOSE WITH ISOLATED EVENTS | 10.47660/CBR.2023.2115 | 2023 |
| CUTANEOUS MANIFESTATIONS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) BEWARE OF LIVEDO RETICULARIS | 10.47660/CBR.2023.2110 | 2023 |
| EVALUATION OF THE QUALITY OF ANTICOAGULATION IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME TREATED WITH WARFARIN | 10.47660/CBR.2023.1969 | 2023 |
| AB0573¿REASONS FOR BREASTFEEDING AVOIDANCE: A MULTICENTER INSIGHT IN MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | 10.1136/annrheumdis-2023-eular.2271 | 2023 |
| Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up | 2022 | |
| AMAUROSIS FUGAX IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: DATA FROM APS-RIO COHORT | 10.47660/CBR.2022.1975 | 2022 |
| Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual [abstract] | 2022 | |
| IgA anticardiolipin isotype is not relevant in Brazilian primary antiphospholipid syndrome patients | 10.47660/cbr.2021.1842 | 2021 |
| Hematological manifestations in patients with antiphospholipid antibodies | 10.47660/cbr.2021.1858 | 2021 |
| Immunogenicity and safety after SARS-CoV-2 vaccine in Primary Antiphospholipid Syndrome (PAPS) | 10.47660/cbr.2021.1888 | 2021 |
| Mobile thrombi in cardiac implantable electronic device in a patient with antiphospholipid syndrome as a risk factor for the development of symptomatic pulmonary embolism: Case Report | 10.47660/cbr.2020.16873 | 2021 |
| Comparison of clinical and laboratory characteristics of patients with early vs. late onset Primary Antiphospholipid Syndrome | 10.47660/cbr.2020.16700 | 2021 |
| Avoiding misclassification of primary antiphospholipid syndrome as systemic lupus erythematosus: what are the best-performing SLE classification criteria?. | 2020 | |
| Recurrent early pregnancy loss is associated with higher aGAPSS in thrombotic Primary Antiphospholipid Syndrome. | 2019 | |
| Thrombocytopenia is highly associated with specific antiphospholipid antibodies profiles | 2019 | |
| Non-criteria manifestations, antiphospholipid profile and their associations in primary antiphospholipid syndrome (PAPS) | 2018 | |
| Arterial events in primary antiphospholipid syndrome (PAPS): Don't forget the traditional cardiovascular risk factors | 2018 | |
| THU0253¿Triple positivity to antiphospholipid antibodies in primary antiphospholipid syndrome: increased risk of arterial thromboses and abortions | 10.1136/annrheumdis-2017-eular.6774 | 2017 |
| THU0286¿Recurrence of arterial and venous thromboses in primary antiphospholipid syndrome | 10.1136/annrheumdis-2017-eular.6981 | 2017 |
| SAT0303¿Clinical differences between definite and probable antiphospholipid (APS) patients: should they be treated the same? | 10.1136/annrheumdis-2017-eular.6987 | 2017 |
| Avaliação da Monitorização da Anticoagulação de pacientes com Síndrome do Anticorpo Antifosfolipidio (SAF) e sua correlação com desfechos clínicos | 2017 | |
| Avaliação da Plaquetopenia relacionada aos Anticorpos Antifosfolipídios | 2017 | |
| Tripla positividade aos anticorpos antifosfolipídios: aumento do risco de manifestações gestacionais | 2017 | |
| Arterial Events in Primary Antiphospholipid Syndrome are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score | 2016 | |
| Anticorpos da Síndrome do Anticorpo Antifosfolipídio e suas associações clínicas: a importância da anti B2 glicoproteína | 2016 | |
| Avaliação das manifestações clínicas que não constam na classificação da Síndrome do Anticorpo Antifosfolipidio em pacientes com anticorpos persistentes | 2016 | |
| Doença cerebrovascular na Síndrome do Anticorpo Antifosfolipídio | 2016 | |
| Risk factors associated with clinical classification criteria in primary antiphospholipid syndrome: the impacte of triple positive | 2016 | |
| Thrombocytopenia in primary antiphospolipid syndrome is associated with anticardiolipin but not with other antiphospholipid antibodies | 2016 | |
| Long-term thalidomide use in refractory cutaneous lesions of lupus erythemathosus. | 2007 | |
| Ação dos Antimaláricos no Perfil Lipídico de Pacientes com Lúpus Eritematoso Sistêmico. | 2004 | |
| Prevalência de Dislipidemias e Seus Fatores de Risco em Pacientes com Lúpus Eritematoso Sistêmico | 2004 |